Cat. #156372
PKCa cell line
Cat. #: 156372
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Availability: 10-12 weeks
Organism: Human
Tissue: Breast
Disease: Cancer
Model: Cancer Model
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Debra Tonetti
Institute: University of Illinois Chicago
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: PKCa cell line
- Alternate name: MCF7
- Cancer: Breast cancer
- Cancers detailed: Breast cancer;Tamoxifen Resistance
- Research fields: Cancer;Drug development
- Tool sub type: Continuous
- Parental cell: MCF-7
- Organism: Human
- Tissue: Breast
- Disease: Cancer
- Model: Cancer Model
- Description: Approximately 70% of breast cancer patients have estrogen receptor positive (ER+) tumors. The selective estrogen receptor modulator (SERM), tamoxifen, and aromatase inhibitors (AIs) represent first-line treatment for ER+ patients however, up to 50% of patients either do not respond or acquire resistance within 5 years of treatment. The MCF7-PKCa cell line was engineered to exogenously overexpress Protein Kinase C alpha (PKCa) which rendered it resistant to tamoxifen. MCF7-PKCa represents a valuable model for tamoxifen resistance and for screening the effectiveness of alternatives.
- Additional notes: Engineered to over-express PKCa.
Target Details
- Target: PKCÄÂ?Â
Applications
- Application notes: Engineered to over-express PKCÄÂ? .
Handling
- Format: Frozen
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Xiong et al. 2017. J Med Chem. 60(4):1325-1342. PMID: 28117994.
